Inz-1

CAS No. 897776-15-7

Inz-1( Inz1 | Inz 1 )

Catalog No. M27886 CAS No. 897776-15-7

Inz-1 is an effective and fungal-selective inhibitor of mitochondrial cytochrome bc1 with IC50s of 8.092 and 45.320 μM for yeast and human.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 142 Get Quote
10MG 239 Get Quote
25MG 430 Get Quote
50MG 628 Get Quote
100MG 896 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Inz-1
  • Note
    Research use only, not for human use.
  • Brief Description
    Inz-1 is an effective and fungal-selective inhibitor of mitochondrial cytochrome bc1 with IC50s of 8.092 and 45.320 μM for yeast and human.
  • Description
    Inz-1 is an effective and fungal-selective inhibitor of mitochondrial cytochrome bc1 with IC50s of 8.092 and 45.320 μM for yeast and human. Inz-1 reverses Fluconazole or other triazole antifungals’ resistance in the pathogenic fungus Candida albicans.(In Vitro):Inz-1 against Candida and HepG2 respiring growth with IC50 values of 1.655 uM and >32 μM, respectively. Inz-1 (0-16 μM; 24 hours) inhibits the growth of the model yeast S. cerevisiae (strain BY4741) and C. albicans (SC5314) in media containing glucose or glycerol as the sole carbon source, while only mildly slowing growth in glucose. Inz-1 (0-100 μM; 24 hours) shows inhibition of yeast cytochrome B enzymatic activity in a concentration -dependent manner in both wild-type and F90Y mutant mitochondria. It exhibits inhibition of cytochrome bc1 from both S. cerevisiae and C. albicans with IC50 value of 2.5 μM and 8.0 μM, respectively. Inz-1 (0-100 μM; 24 hours) inhibits proliferation under forced respiration conditions only at 32 μM and only mildly at that concentration.
  • In Vitro
    Inz-1 (0-16 μM; 24 hours) inhibits the growth of the model yeast?S. cerevisiae?(strain BY4741) and?C. albicans?(SC5314) in media containing glucose or glycerol as the sole carbon source, while only mildly slowing growth in glucose.?Inz-1 (0-100 μM; 24 hours) shows inhibition of yeast cytochrome B enzymatic activity in a concentration -dependent manner in both wild-type and F90Y mutant mitochondria. It exhibits inhibition of cytochrome bc1 from both?S. cerevisiae and?C. albicans?with IC50 value of 2.5 μM and 8.0 μM, respectively.Inz-1 (0-100 μM; 24 hours) is selective for yeast over human cytochrome bc1, it inhibits human cytochrome bc1 activity only weakly, with an IC50?of 45.3 μM, 5.6-fold higher than the IC50?for the?C. albicans?homolog in mitochondria purified from HEK293 human embryonic kidney cells.Inz-1 (0-100 μM; 24 hours) inhibits proliferation under forced respiration conditions only at 32 μM,and only mildly at that concentration.Inz-1 is against candida, human enzyme with IC50 values of 8.092μM and 45.320 μM, respectively. It against Candida and HepG2 respiring growth with IC50 values of 1.655 uM and >32 μM, respectively.
  • In Vivo
    ——
  • Synonyms
    Inz1 | Inz 1
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    P450
  • Recptor
    Carbonic anhydrase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    897776-15-7
  • Formula Weight
    266.3
  • Molecular Formula
    C16H14N2O2
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COC(=O)Cn1nc(-c2ccccc2)c2ccccc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Milburn-McNulty P, et al. Sulthiame add-on therapy for epilepsy. Cochrane Database Syst Rev. 2015 Oct 28;(10):CD009472.
molnova catalog
related products
  • Cholesterol 24-hydro...

    Cholesterol 24-hydroxylase-IN-1 is an orally active, selective, and potent inhibitor of cholesterol 24-hydroxylase (CH24H or CYP46A1) that crosses the blood-brain barrier.

  • CAY10462

    CAY10462 (CTK8E8405) is an effective and selective inhibitor of the 20-HETE synthase CYP4A11 with an IC50 of 8.8 nM.

  • Ambroxol

    Ambroxol is indicated as "secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.